This article was originally published in The Gray Sheet
Executive SummaryLaser eye surgery provider TLC will adopt Nestle subsidiary Alcon's LADARVision 4000 next generation flying-spot small beam ophthalmic laser system as its primary platform in its refractive centers under a multi-year technology alliance announced Feb. 22
You may also be interested in...
The US FDA has slapped a partial clinical hold on Ipsen’s palovarotene clinical trials in rare bone disorders in children less than 14 years old, due to bone growth concerns.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced October to November.